📊 RGNX Key Takeaways
Is REGENXBIO Inc. (RGNX) a Good Investment?
RGNX is a biotech company with structurally unsustainable economics: $170M in revenue generates -$194M net losses and -$124M in operating cash burn annually, leaving only 3-4 months of cash runway at current burn rates. Flat YoY revenue growth combined with deepening losses and negative free cash flow of -$126M indicates the company is not advancing toward profitability and faces severe liquidity risk without immediate capital raises or dramatic operational improvements.
Fundamentals are weak: losses are large and persistent with operating and net margins deeply negative, while revenue growth is flat. Although the company carries no debt and maintains a solid current ratio, cash on hand appears insufficient relative to the heavy operating cash burn, implying near‑term financing risk. Without clear improvement in revenue traction or cost discipline, the risk/reward skews unfavorably.
Why Buy REGENXBIO Inc. Stock? RGNX Key Strengths
- No long-term debt (Debt/Equity: 0.00x) reduces financial distress risk
- Current liquidity ratio of 2.38x provides near-term operational flexibility
- EPS deterioration slowed YoY (+18.1%), suggesting modest operational improvements
- Debt-free balance sheet (0.00x D/E)
- Solid liquidity (2.38x current and quick ratios)
- Low capital intensity (minimal capex)
RGNX Stock Risks: REGENXBIO Inc. Investment Risks
- Critical cash burn of -$124M annually against only -$34.5M cash reserves (~3 month runway)
- Flat revenue growth (-0% YoY) while losses persist indicates no commercial traction or market acceptance
- Operating margin of -94.6% and net margin of -113.8% show severe operational unprofitability unsustainable long-term
- Negative free cash flow of -$126.4M and ROE of -188.7% demonstrate value destruction
- Sustained large operating losses (-94.6% operating margin)
- Heavy negative free cash flow versus limited cash ($34.5M)
- Flat revenue (+0.0% YoY) with uncertain visibility
Key Metrics to Watch
- Operating cash flow trend and monthly burn rate sustainability
- Revenue growth acceleration and path to gross profitability
- Cash balance depletion rate and need for capital raise timing
- Operating cash flow (burn rate)
- Revenue growth YoY
REGENXBIO Inc. (RGNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.38x current ratio provides a solid financial cushion.
RGNX Profit Margin, ROE & Profitability Analysis
RGNX vs Healthcare Sector: How REGENXBIO Inc. Compares
How REGENXBIO Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is REGENXBIO Inc. Stock Overvalued? RGNX Valuation Analysis 2026
Based on fundamental analysis, REGENXBIO Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
REGENXBIO Inc. Balance Sheet: RGNX Debt, Cash & Liquidity
RGNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: REGENXBIO Inc.'s revenue has declined by 64% over the 5-year period, indicating business contraction. The most recent EPS of $-4.59 indicates the company is currently unprofitable.
RGNX Revenue Growth, EPS Growth & YoY Performance
RGNX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $24.2M | -$59.6M | $-1.17 |
| Q2 2025 | $21.4M | -$53.0M | $-1.05 |
| Q1 2025 | $15.6M | $6.1M | $0.12 |
| Q3 2024 | $24.2M | -$59.6M | $-1.17 |
| Q2 2024 | $20.0M | -$53.0M | $-1.05 |
| Q1 2024 | $15.6M | -$63.3M | $-1.38 |
| Q3 2023 | $26.5M | -$61.9M | $-1.41 |
| Q2 2023 | $20.0M | -$68.2M | $-1.58 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
REGENXBIO Inc. Dividends, Buybacks & Capital Allocation
RGNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for REGENXBIO Inc. (CIK: 0001590877)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RGNX
What is the AI rating for RGNX?
REGENXBIO Inc. (RGNX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RGNX's key strengths?
Claude: No long-term debt (Debt/Equity: 0.00x) reduces financial distress risk. Current liquidity ratio of 2.38x provides near-term operational flexibility. ChatGPT: Debt-free balance sheet (0.00x D/E). Solid liquidity (2.38x current and quick ratios).
What are the risks of investing in RGNX?
Claude: Critical cash burn of -$124M annually against only -$34.5M cash reserves (~3 month runway). Flat revenue growth (-0% YoY) while losses persist indicates no commercial traction or market acceptance. ChatGPT: Sustained large operating losses (-94.6% operating margin). Heavy negative free cash flow versus limited cash ($34.5M).
What is RGNX's revenue and growth?
REGENXBIO Inc. reported revenue of $170.4M.
Does RGNX pay dividends?
REGENXBIO Inc. does not currently pay dividends.
Where can I find RGNX SEC filings?
Official SEC filings for REGENXBIO Inc. (CIK: 0001590877) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RGNX's EPS?
REGENXBIO Inc. has a diluted EPS of $-3.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RGNX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, REGENXBIO Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RGNX stock overvalued or undervalued?
Valuation metrics for RGNX: ROE of -188.7% (sector avg: 15%), net margin of -113.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RGNX stock in 2026?
Our dual AI analysis gives REGENXBIO Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RGNX's free cash flow?
REGENXBIO Inc.'s operating cash flow is $-124.0M, with capital expenditures of $2.4M. FCF margin is -74.1%.
How does RGNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -113.8% (avg: 12%), ROE -188.7% (avg: 15%), current ratio 2.38 (avg: 2).